Serial measurement of pancreatic lipase immunoreactivity concentration in dogs with immune‐mediated disease treated with prednisolone

• DOI: 10.1111/jsap.12652
• Publication Date: 2017-03-01T11:39:41Z
• Authors: H. Ohta; T. Morita; N. Yokoyama; T. Osuga; N. Sasaki; K. Morishita; K. Nakamura; M. Takiguchi
• Keywords: Prednisolone; Subclinical infection

In this pilot study, serum canine pancreatic lipase immunoreactivity was measured repeatedly in dogs with various immune-mediated diseases that were treated immunosuppressive doses of prednisolone.Ten client-owned newly diagnosed disease had normal concentrations (≤200 µg/l) 2 to 2.2 mg/kg prednisolone orally once daily as the initial treatment. Serum samples obtained from each prior treatment and at 1- 4-week intervals during The highest concentration detected defined peak immunoreactivity.Peak classified two dogs, questionable (201 399 three abnormal (≥400 five dogs. Peak significantly higher than baseline but there no evidence clinical pancreatitis.It remains unclear whether 10 elevated prednisone subclinical pancreatitis or results a consequence administration.